SuspendedNot Applicable

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

Stopped: As a part of portfolio and planning reassessment for the current period, a decision has been made to prioritize, optimize and reallocate resources. As a result, enrollment and other study activities have been temporarily paused.

Russia100 participantsStarted 2025-12-23

Plain-language summary

This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adults (≥18 years) with a confirmed diagnosis of AQP4-IgG positive NMOSD following the 2015 IPND criteria;
. Provision of signed and dated written informed consent.

Exclusion criteria

.Participants currently enrolled in clinical studies for the treatment of NMOSD.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Baseline demographics and clinical characteristics

Timeframe: At inclusion

Pre-inclusion relapse history

Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)

Pre-inclusion NMOSD-related hospitalizations

Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)

Time from first symptoms to NMOSD diagnosis

Timeframe: From first NMOSD symptoms to date of diagnosis (retrospective baseline)

Prior misdiagnoses profile

Timeframe: From first NMOSD symptoms to confirmed NMOSD diagnosis (retrospective baseline)

AQP4-IgG testing method

Timeframe: At time of NMOSD diagnostic workup (retrospective baseline)

MRI brain T2-hyperintense lesion count change

Timeframe: Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion

Trial details

NCT IDNCT07247292

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-12-31

View on ClinicalTrials.gov More Rare Diseases trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adults (≥18 years) with a confirmed diagnosis of AQP4-IgG positive NMOSD following the 2015 IPND criteria;
. Provision of signed and dated written informed consent.

Exclusion criteria

.Participants currently enrolled in clinical studies for the treatment of NMOSD.

What they're measuring

Baseline demographics and clinical characteristics

Timeframe: At inclusion

Pre-inclusion relapse history

Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)

Pre-inclusion NMOSD-related hospitalizations

Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)

Time from first symptoms to NMOSD diagnosis

Timeframe: From first NMOSD symptoms to date of diagnosis (retrospective baseline)

Prior misdiagnoses profile

Timeframe: From first NMOSD symptoms to confirmed NMOSD diagnosis (retrospective baseline)

AQP4-IgG testing method

Timeframe: At time of NMOSD diagnostic workup (retrospective baseline)

MRI brain T2-hyperintense lesion count change

Timeframe: Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion